Shizuya Yamashita

Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects.

Satoshi Nozaki, Hirokazu Kashiwagi, Shizuya Yamashita et al. · Journal of Clinical Investigation · 1995 · 341 citations · Full text

Inflammation, Cd36-deficient Macrophages, Reduced Uptake +15

Effects of K-877, a novel selective PPARα modulator (SPPARMα), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial

Shun Ishibashi, Shizuya Yamashita, Hidenori Arai et al. · Atherosclerosis · 2016 · 208 citations · Full text

Oxidized LDL–Induced NF-κB Activation and Subsequent Expression of Proinflammatory Genes Are Defective in Monocyte-Derived Macrophages From CD36-Deficient Patients

Mohamed Janabi, Shizuya Yamashita, Ken‐ichi Hirano et al. · Arteriosclerosis Thrombosis and Vascular Biology · 2000 · 199 citations

Vascular Disease, Immunology, Immune Regulation +25

CD36 deficiency associated with insulin resistance

Koji Miyaoka, Takahiro Kuwasako, Ken‐ichi Hirano et al. · The Lancet · 2001 · 191 citations

Metabolic Syndrome, Diabetes, Immunology +6

Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Shun Ishibashi, Hidenori Arai, Koutaro Yokote et al. · Journal of clinical lipidology · 2017 · 182 citations · Full text